Cart
sales@molnova.com
CDK4/6-IN-2
CAS No. 1800506-48-2
CDK4/6-IN-2( —— )
Catalog No. M23813 CAS No. 1800506-48-2
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 227 | In Stock |
|
| 10MG | 359 | In Stock |
|
| 25MG | 592 | In Stock |
|
| 50MG | 817 | In Stock |
|
| 100MG | 1144 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK4/6-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
-
DescriptionCDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
-
In VitroCDK4/6-IN-2 inhibits H358, H441, PC3, MV-4-11, JeKo-1, SW780, and HGC-27 cells with IC50s of 290.9, 147.8, 260.5, 139, 36.98, 162.5, and 316.4 nM, respectively.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK4|CDK6
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1800506-48-2
-
Formula Weight506.59
-
Molecular FormulaC27H32F2N8
-
Purity>98% (HPLC)
-
SolubilityDMSO:5mg/mL (9.87 mM; Need ultrasonic)
-
SMILESCC(N1C2=CC(C3=CC(NC4=NC=C(CN5CCN(CC)CC5)C=N4)=NC=C3F)=CC(F)=C2N=C1C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Frank Wu, et al. Kinase inhibitor and use thereof. US20180000819A1.
molnova catalog
related products
-
Mevociclib
Mevociclib is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
-
BUR1
BUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
-
SEL120-34A
SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.
